Skip to main content
Full access
Letter to the Editor
Published Online: 1 August 2004

C-Reactive Protein and Serotonin Syndrome

Publication: American Journal of Psychiatry
To the Editor: Serotonin syndrome is an occasionally fatal medication side effect. Because serotonergic agents, including antidepressant medications, are widely prescribed, identifying risk factors for serotonin syndrome is important. Abnormalities of serovascular serotonergic mechanisms, as occur in angina and hypertension, may increase susceptibility to serotonin syndrome (1). We present a case in which the severity of symptoms of serotonin syndrome fluctuated with serum levels of C-reactive protein.
Mr. A was a 53-year-old hypertensive man who was hospitalized for depression. Mr. A was given a prescription for fluoxetine; his outpatient psychotropics—clonazepam, tramadol, and trazodone—were continued. On hospital day 6, Mr. A became acutely confused and had visual hallucinations, gastrointestinal distress, fever, tachycardia, edema, and a fine petechial rash of the lower extremities. Infection or vasculitis was considered, given the rash and abdominal symptoms. A computerized tomography scan of his head, magnetic resonance imaging, and magnetic resonance angiography were negative for a cerebrovascular accident and vasculitis. An EEG twice gave normal results. Other normal laboratory results included a lumbar puncture, two negative qualitative serum antinuclear antibody levels, a cardiac enzyme level, a CBC, comprehensive serum chemistries, and coagulation studies. However, Mr. A’s C-reactive protein was elevated, at 19.2 mg/dl (normal=0 to 0.6 mg/dl). Serotonin syndrome was diagnosed, with symptoms consistent with this and multiple medications with serotonergic activity. Fluoxetine, tramadol, and trazodone were discontinued, and the serotonergic blocker cyproheptadine was begun. By hospital day 22, free of symptoms of serotonin syndrome, Mr. A’s C-reactive protein level was 9.6 mg/dl. Three months later, he remained well, and his C-reactive protein level was 1.7 mg/dl.
Serotonin syndrome occurs when an acute increase in extracellular serotonin faces impaired serotonin metabolism. Vascular disease and depression are both linked to elevated C-reactive protein levels (2, 3). The effect of drugs on C-reactive protein levels is just beginning to be investigated; as yet, none of the medications taken by our patient is known to alter C-reactive protein levels. C-reactive protein activates platelets, promotes the release of serotonin, and inhibits endothelial nitric oxide synthase (4). Nitric oxide is an important endogenous “off” signal for the release and action of platelet-derived serotonin (5). C-reactive protein may contribute to the pathophysiology of the serotonin syndrome by perpetuating the release of platelet-derived serotonin and inhibiting endothelial nitric oxide synthase. Our patient’s serum C-reactive protein level correlated with the course and severity of serotonin syndrome. C-reactive protein levels may help to predict patients at risk for development of serotonin syndrome.

References

1.
Sternbach H: Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Curr Psychiatry 2003; 2:12–24
2.
Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA: Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90:1279–1283
3.
Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H: Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167:73–79
4.
Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439–1441
5.
Tanner FC, Boulanger CM, Luscher TF: Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost 1993; 19:167–175

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1499

History

Published online: 1 August 2004
Published in print: August 2004

Authors

Details

THOMAS M. BROWN, M.D.
San Antonio, Tex.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share